New CAR-T therapy targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new treatment called PTC13, which uses specially engineered immune cells (CAR-T cells) to attack cancer cells that have a protein called CEA. The study includes 18 adults with advanced colorectal, stomach, pancreatic, or other solid tumors that have…
Phase: PHASE1 • Sponsor: Weijia Fang, MD • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC